Inventor · disambiguated record
Roland A. Newman
Also filed as: NEWMAN ROLAND · NEWMAN ROLAND A · NEWMAN ROLAND ANTHONY · REFF MITCHELL E
30 granted patents·10 pending applications·5,907 citations·filing 1993–2024
98Inventor score
Files withIDEC PHARMA CORP20BIOGEN IDEC INC9MITSUBISHI TANABE PHARMA CORP6BLACK AMELIA2IDEC PHARMACEUTICALS1
Top patents by PatentIndex Score
40 records- 0199US7422739B2Anti-CD20 antibodiesBIOGEN IDEC INC·Filed 2001·Granted Sep 9, 2008·166 cites·13 claims
- 0299US5736137ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1993·Granted Apr 7, 1998·1.6k cites·6 claims
- 0398US6399061B1Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jun 4, 2002·254 cites·7 claims
- 0498US5843439ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaFiled 1995·Granted Dec 1, 1998·336 cites·7 claims
- 0598US5776456ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jul 7, 1998·527 cites·14 claims
- 0698US5693780ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Dec 2, 1997·485 cites·16 claims
- 0798US5658570ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Aug 19, 1997·695 cites·38 claims
- 0897US6682734B1Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jan 27, 2004·176 cites·13 claims
- 0997US6136310ARecombinant anti-CD4 antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Oct 24, 2000·186 cites·16 claims
- 1097US5811524ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1995·Granted Sep 22, 1998·205 cites·11 claims
- 1197US5750105ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted May 12, 1998·318 cites·10 claims
- 1296US7381560B2Expression and use of anti-CD20 antibodiesBIOGEN IDEC INC·Filed 2001·Granted Jun 3, 2008·45 cites·10 claims
- 1396US6001358AHumanized antibodies to human gp39, compositions containing thereofIDEC PHARMA CORP·Filed 1995·Granted Dec 14, 1999·125 cites·12 claims
- 1496US5756096ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted May 26, 1998·175 cites·6 claims
- 1596US5681722ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Oct 28, 1997·158 cites·8 claims
- 1694US5866125ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Feb 2, 1999·86 cites·5 claims
- 1793US7744877B2Expression and use of anti-CD20 AntibodiesBIOGEN IDEC INC·Filed 2002·Granted Jun 29, 2010·38 cites·8 claims
- 1893US7338658B2Recombinant anti-CD4 antibodies for human therapyBIOGEN IDEC INC·Filed 2002·Granted Mar 4, 2008·36 cites·7 claims
- 1993US5939068ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Aug 17, 1999·83 cites·7 claims
- 2093US5840298ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Nov 24, 1998·75 cites·11 claims
- 2191US5955364ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Sep 21, 1999·63 cites·9 claims
- 2285US7122187B2Treating autoimmune diseases with humanized anti-CD40L antibodyBIOGEN IDEC INC·Filed 2002·Granted Oct 17, 2006·23 cites·8 claims
- 2385US7074406B2Treating allergic diseases with humanized anti-CD40L antibodyBIOGEN IDEC INC·Filed 2002·Granted Jul 11, 2006·14 cites·9 claims
- 2482US10323095B2Antibody-fynomer conjugatesMITSUBISHI TANABE PHARMA CORP·Filed 2015·Granted Jun 18, 2019·7 cites·20 claims
- 2580US6440418B1Methods of treating autoimmune diseases with gp39-specific antibodiesIDEC PHARMA CORP·Filed 1997·Granted Aug 27, 2002·36 cites·16 claims
- 2678US7452534B1Recombinant anti-CD4 antibodies for human therapyBIOGEN IDEC INC·Filed 2000·Granted Nov 18, 2008·7 cites·18 claims
- 2775US11299547B2CMET monoclonal binding agents, drug conjugates thereof and uses thereofMITSUBISHI TANABE PHARMA CORP·Filed 2017·Granted Apr 12, 2022·2 cites·20 claims
- 2871US2025032632A1DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOFMITSUBISHI TANABE PHARMA CORP·Filed 2024·Application pending·0 cites
- 2966US2009221036A1Recombinant anti-cd4 antibodies for human therapyBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 3065US2009226430A1Recombinant anti-cd4 antibodies for human therapyBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 3160US2005186205A1Therapeutic application of chimeric and radiolabeled antibodies to human B Lymphocyte restricted differentiation antigen for treatment of B cell LymphomaFiled 2004·Application pending·0 cites
- 3260US2003021781A1Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 3359US2006147446A1Humanized antibodies to human GP39, compositions, and therapeutic uses thereofBLACK AMELIA·Filed 2006·Application pending·0 cites
- 3458US12060427B2Drug conjugates of cMET monoclonal binding agents, and uses thereofMITSUBISHI TANABE PHARMA CORP·Filed 2019·Granted Aug 13, 2024·0 cites·16 claims
- 3558US6506383B1Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodiesIDEC PHARMA CORP·Filed 1999·Granted Jan 14, 2003·9 cites·27 claims
- 3656US2006153837A1Treating autoimmune diseases with humanized anti-CD401 antibodiesBLACK AMELIA·Filed 2006·Application pending·0 cites
- 3751US2002150580A1Recombinant antibodies for human therapyIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 3848US2003082172A1Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMACEUTICALS·Filed 2002·Application pending·0 cites
- 3945US2022249679A1Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptorMITSUBISHI TANABE PHARMA CORP·Filed 2019·Application pending·0 cites
- 4036US11242403B2Syndecan-1 (CD138) binding agents and uses thereofMITSUBISHI TANABE PHARMA CORP·Filed 2018·Granted Feb 8, 2022·0 cites·23 claims
Join the waitlist — get patent alerts
Get an alert when Roland A. Newman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →